ChosenMed and Leto Laboratories Entered into a Strategic Cooperation on Predictive and Prognostic Molecular Marker Research for Solid Tumor Immunotherapy
On 19 January 2021, ChosenMed Technology (Beijing) Co., Ltd. (“ChosenMed”) and Leto Laboratories Co., Ltd. (“Leto Laboratories”) signed a strategic cooperation agreement in Beijing, to research in tandem on predictive and prognostic molecular markers for immunotherapy in solid tumors and advance the registration of companion diagnostic devices.
Published: January 19, 2021
Leto Laboratories Grants Exclusive License to TopAlliance (01877) for an Interleukin-2 (IL-2) Drug
(ZhiTong Financial Information Technology, News on App)- TopAlliance (01877) announced the signing of an agreement with Leto Laboratories Co., Ltd. (Leto Laboratories), the“Technology License Contract for an IL-2 Drug with Unique Intramolecular Disulfide Bonds”. TopAlliance is exclusively licensed for the preclinical development, clinical research, and commercialization of this IL-2 drug (Code Name: LTC002) and for the use of related patented technology worldwide.
Published: August 28，2020
State-of-the-Art Technology Facilitates Protein Manufacturing
Today let me introduce a successful case related to this topic- how Leto Laboratories Co., Ltd. develops and manufactures ACE2, a recombinant protein, with BioAccord system of Waters. This system has been used for virus research, development and quality control of vaccines, diagnostic reagents and therapeutic medications in many world-renowned research institutions and firms.
Published: May 15 ，2020
No more data……